{"count":16,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/","filing_uuid":"98b78028-f7ec-4e4b-bf36-4f196ec79a0e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-07-17T06:31:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/","filing_uuid":"98b78028-f7ec-4e4b-bf36-4f196ec79a0e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-07-17T06:31:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/","filing_uuid":"98b78028-f7ec-4e4b-bf36-4f196ec79a0e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-07-17T06:31:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/","filing_uuid":"98b78028-f7ec-4e4b-bf36-4f196ec79a0e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-07-17T06:31:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/","filing_uuid":"98b78028-f7ec-4e4b-bf36-4f196ec79a0e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-07-17T06:31:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/","filing_uuid":"98b78028-f7ec-4e4b-bf36-4f196ec79a0e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/98b78028-f7ec-4e4b-bf36-4f196ec79a0e/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-07-17T06:31:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for introduction of S. 4941 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter raising concerns that new draft guidance from the Food and Drug Administration (FDA) could lead to the authorization of more flavored products that have historically appealed to youth. Met with Centers for Medicare & Medicaid Services (CMS) regarding updates to Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards, as well as CMS' CRUSH initiative. Met with SAMHSA regarding clinical policy support and methadone integration","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b16a8130-a66e-44ee-ae12-b27589f29726/","filing_uuid":"b16a8130-a66e-44ee-ae12-b27589f29726","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/b16a8130-a66e-44ee-ae12-b27589f29726/print/","filing_document_content_type":"text/html","income":null,"expenses":"69462.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Colette Alston","dt_posted":"2026-07-20T08:40:01-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 12th Street NW","registrant_address_2":"Suite 700","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":400577734,"url":"https://lda.gov/api/v1/registrants/400577734/","house_registrant_id":null,"name":"ASSOCIATION FOR BEHAVIORAL HEALTH AND WELLNESS","description":"ABHW is the national voice for companies that manage behavioral health & wellness services","address_1":"700 12th Street NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"COLETTE ALSTON","contact_telephone":"+1 202-499-2280","dt_updated":"2026-07-20T08:21:58.745723-04:00"},"client":{"id":192996,"url":"https://lda.gov/api/v1/clients/192996/","client_id":12,"name":"ASSOCIATION FOR BEHAVIORAL HEALTH AND WELLNESS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-11-21"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-Suicide prevention and crisis services -Behavioral Health Workforce Shortages - Mental Health and Substance Use Disorder Parity - advocating for uniformity and clearer regulations for non-quantitative treatment limitations - Telehealth Expansion Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71094,"prefix":null,"prefix_display":null,"first_name":"MAEGHAN","nickname":null,"middle_name":null,"last_name":"GILMORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141004,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148243,"prefix":"ms","prefix_display":"MS.","first_name":"DEBORAH","nickname":null,"middle_name":"MILLER","last_name":"WITCHEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":154409,"prefix":null,"prefix_display":null,"first_name":"LYDIA","nickname":null,"middle_name":null,"last_name":"HOMOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"},{"id":41,"name":"Treasury, Dept of"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"-Expand access to medication-assisted treatment -Drug Enforcement Agency (DEA) - rules for prescribing controlled medications via telemedicine -Contingency Management -Modernizing Opioid Treatment Access Act (MOTAA) 2.0 (S. 4941) -H.R. 5629 - bill to nullify SAMHSA rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71094,"prefix":null,"prefix_display":null,"first_name":"MAEGHAN","nickname":null,"middle_name":null,"last_name":"GILMORE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":141004,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148243,"prefix":"ms","prefix_display":"MS.","first_name":"DEBORAH","nickname":null,"middle_name":"MILLER","last_name":"WITCHEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154409,"prefix":null,"prefix_display":null,"first_name":"LYDIA","nickname":null,"middle_name":null,"last_name":"HOMOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"},{"id":41,"name":"Treasury, Dept of"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"-Telehealth, reforming barriers to access to services. Extending flexibilities and repealing the 6-month in person visit requirement. -The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act -Medicaid reform -Medicaid community engagement requirements -42 CFR Part 2 as it relates to Medicaid community engagement requirements -Coverage of Peer Support specialists' services","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71094,"prefix":null,"prefix_display":null,"first_name":"MAEGHAN","nickname":null,"middle_name":null,"last_name":"GILMORE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":141004,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148243,"prefix":"ms","prefix_display":"MS.","first_name":"DEBORAH","nickname":null,"middle_name":"MILLER","last_name":"WITCHEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154409,"prefix":null,"prefix_display":null,"first_name":"LYDIA","nickname":null,"middle_name":null,"last_name":"HOMOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"},{"id":41,"name":"Treasury, Dept of"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/6336a8b2-47cd-4f59-a4ef-bb5dd0484c68/","filing_uuid":"6336a8b2-47cd-4f59-a4ef-bb5dd0484c68","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/6336a8b2-47cd-4f59-a4ef-bb5dd0484c68/print/","filing_document_content_type":"text/html","income":null,"expenses":"520000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"William B Tanner","dt_posted":"2026-10-16T17:32:53-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 FIRST STREET, NE","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":60138,"url":"https://lda.gov/api/v1/registrants/60138/","house_registrant_id":35338,"name":"AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES INC.(FKA AMERICAN PSYCHOLOGICAL ASSN","description":null,"address_1":"750 FIRST STREET, NE","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM TANNER","contact_telephone":"+1 202-336-5889","dt_updated":"2026-07-16T19:17:12.861178-04:00"},"client":{"id":160882,"url":"https://lda.gov/api/v1/clients/160882/","client_id":12,"name":"AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES INC.(FKA AMERICAN PSYCHOLOGICAL ASSN","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-01"},"lobbying_activities":[{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"H.R. 1246 Investing in Rural America Act H.R. 4400 / S. 2282 Farmers First Act H.R. 7567 Farm, Food, and National Security Act (Farm Bill) General access to behavioral health in rural America","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83012,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"STRICKLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY2027 Labor-HHS-Education Appropriations FY2027 Military Construction, Veteran Affairs, and Related Agencies FY26 DHS Minibus Package OMB proposed grants rule FY2027 IHS Appropriations","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":75773,"prefix":null,"prefix_display":null,"first_name":"KENNETH","nickname":null,"middle_name":null,"last_name":"POLISHCHUK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143455,"prefix":"mr","prefix_display":"MR.","first_name":"BENJAMIN","nickname":null,"middle_name":null,"last_name":"VONACHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":121695,"prefix":null,"prefix_display":null,"first_name":"DORIS","nickname":null,"middle_name":null,"last_name":"PARFAITE-CLAUDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141050,"prefix":null,"prefix_display":null,"first_name":"STEFANIE","nickname":null,"middle_name":null,"last_name":"REEVES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145372,"prefix":"ms","prefix_display":"MS.","first_name":"KAREN CONWELL","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140715,"prefix":"mr","prefix_display":"MR.","first_name":"JULIO","nickname":null,"middle_name":"CESAR","last_name":"ABREU","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Promotion Rates for DOD Psychologists Recruitment of DOD Psychologists DOD Congressionally Directed Medical Research Program (CDMRP) H.R. 3906 Medical Research For Our Troops Act FY27 National Defense Authorization Act WARP AI Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145372,"prefix":"ms","prefix_display":"MS.","first_name":"KAREN CONWELL","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"H.R.10421, Transforming Education for the Future Act SOS Campus Act CARE for Student Mental Health Act ACCESS in Mental Health Act NPRM on education grants NPRM on accreditation Ed Tech","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":75773,"prefix":null,"prefix_display":null,"first_name":"KENNETH","nickname":null,"middle_name":null,"last_name":"POLISHCHUK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":32,"name":"Education, Dept of"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FAM","general_issue_code_display":"Family issues/Abortion/Adoption","description":"H.R. 9994 - Family Poverty is Not Child Neglect Act Foster Care","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141050,"prefix":null,"prefix_display":null,"first_name":"STEFANIE","nickname":null,"middle_name":null,"last_name":"REEVES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":131,"name":"Administration for Children & Families (ACF)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R.4484/S.2356, ADAPT Act H.Res.697, Supporting September as National Suicide Prevention Month Budget Reconciliation bill Alleviating Barriers for Caregivers Act Response to FDA proposed industry guidance on AI-enabled device Budget Reconciliation H. R. 912/S. 1007, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 929/S. 266, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 957, Parity Enforcement Act of 2025 H.R 2509/ S. 931, COMPLETE Care Act H.R. 2630, Youth Suicide Prevention Research Act H.R. 3266/ S. 1673, Mental Health Infrastructure Improvement Act H.R.3505/ S. 5558, Barriers to Suicide Act of 2025 H.R. 3624/S.1924, Improving Mental Health Access for Students Act H.R. 5178 /S. 721 Sickle Cell Disease Comprehensive Care Act H.R 4619/S.4076, Medicare Mental Health Inpatient Equity Act H.R. 4744, Community Mental Wellness and Resilience Act of 2025 H.R. 4745/ S.2410, The Medicaid Bump Act H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5482, Prevent Youth Suicide Act H.R.5629, Medications for the Treatment of Opioid Use Disorder H.R.5630, to Require Additional Information in State Plans for SUPTRS Block Grant H.R. 5706, Mental Health Emergency Responder Act H.R. 6396, Kid PROOF Act of 2025 H.R. 6601, CARE for First Responders Act S.683/H.R.7324, More Behavioral Health Providers Act of 2025 S. 1062, Suicide Prevention Act H.R. 2904/S. 1448 Pursuing Equity in Mental Health Act Rural Behavioral Health Improvement Act (H.R. 5217) Therapeutic Fraud Prevention Act (H.R. 3243 / S. 1663) H.R. 12/S. 2150 Womens Health Protection Act of 2025 S.2826/H.R.5434, 988 LGBTQ+ Youth Access Act S. 3431, Improving Measurements for Loneliness and Isolation Act of 2025 Black women and girls mental health Senior Chatbot Protection Act (S. 5117) Docs Not AI Act (TBD)H.R 2587/S.1266 - Youth Mental Health Research Act Coalition Letter to Protect LGBTQ+ dedicated line to 988 S.2826/H.R.5434, 988 LGBTQ+ Youth Access Act H.R. 138 / S. 1565 Lowering Costs for Caregivers Act H.R.7092/S.4061, Raising Awareness for Youth Suicide Prevention Act (RAYS) Act H.R. 7875, Providing Opportunities for Individuals in Need of Treatment and Support Act (POINTS Act) H.R. 7985 CHATBOT Act H.R.8122/ S.4640, 9-8-8 Connect Act H.R.8124, Stabilization to Prevent (STOP) Suicide Act H.R.8201, Require FQHCs to Provide Behavioral and Mental Health and Substance Use Disorder Services H.R.8487/S.3402, Ensuring Excellence in Mental Health Act H.R.9257/S.4754, The Primary and Behavioral Health Care Access Act H.R.9389, Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 H.R.9551, Mental Health Parity Enforcement and Funding Act H.R. 9693, the Patients First Act of 2026 H.R. 9790/S. 4941, Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0) H.R. 9990/S. 5120, Increasing Mental Health Options (IMHO) Act H.R.10280, 9-8-8 Implementation Act of 2026 S.4076/H.R.4619, To End the 190-day Lifetime Limit on Inpatient Psychiatric Care Under Medicare S.5269, Pay PCPs Act of 2026 Access to evidence-based behavioral treatments for substance use disorders Psychedelic Therapies - Training and Policy CMS ACCESS Model FDA Digital Therapeutics CDC Youth Mental Health","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71418,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":"ALISON","last_name":"STUDWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83012,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"STRICKLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141050,"prefix":null,"prefix_display":null,"first_name":"STEFANIE","nickname":null,"middle_name":null,"last_name":"REEVES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140715,"prefix":"mr","prefix_display":"MR.","first_name":"JULIO","nickname":null,"middle_name":"CESAR","last_name":"ABREU","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145372,"prefix":"ms","prefix_display":"MS.","first_name":"KAREN CONWELL","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":75773,"prefix":null,"prefix_display":null,"first_name":"KENNETH","nickname":null,"middle_name":null,"last_name":"POLISHCHUK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"H.R. 4393 The Dignity Act of 2025 H.R. 4954, Immigrants Mental Health Act draft legislation Reintroduction of H.R. 9550, Taking Action to Prevent Suicide Act (TAPS) and general border agent suicide prevention Public Charge Comments for NPRM H.R.7335 Humanitarian Standards for Individuals in ICE and CBP Custody Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"IND","general_issue_code_display":"Indian/Native American Affairs","description":"Medicaid for Native American children Native American student loan repayment Value of Public Health Psychologists in Commissioned Corp of USPHS HR 8318 Tribal Tax and Investment Reform Act IHS Workforce","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":138,"name":"Indian Health Service"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LAW","general_issue_code_display":"Law Enforcement/Crime/Criminal Justice","description":"S.2645 DHS +Suicide Prevention and Resiliency for Law Enforcement Act Intimate Partner Violence S. 2703 Protecting Older Americans Act S. 1820 Protecting Older Workers Against Discrimination Act Draft Legislation First Responder Safe Harbor Act HR 10349 EMT Act Senate Aging Committee written testimony re: financial scams targeting older adults Supporting Blue Envelope Programs Act (H.R. 6602)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143455,"prefix":"mr","prefix_display":"MR.","first_name":"BENJAMIN","nickname":null,"middle_name":null,"last_name":"VONACHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83012,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"STRICKLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145372,"prefix":"ms","prefix_display":"MS.","first_name":"KAREN CONWELL","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":37,"name":"Justice, Dept of (DOJ)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"S. 2703 Protecting Older Americans Act S. 1820 Protecting Older Workers Against Discrimination Act S. 4916 Aging with Artificial Intelligence Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83012,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"STRICKLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145372,"prefix":"ms","prefix_display":"MS.","first_name":"KAREN CONWELL","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":37,"name":"Justice, Dept of (DOJ)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Preservation of access to Medicaid H.R 4619, Medicare Mental Health Inpatient Equity Act H.R. 4745/ S.2410, The Medicaid Bump Act H.R. 9693, the Patients First Act of 2026 H.R. 9990/S. 5120, Increasing Mental Health Options (IMHO) Act S.683/H.R.7324, More Behavioral Health Providers Act of 2025 S. 931/H.R. 2509, COMPLETE Care Act S.5269, Pay PCPs Act of 2026 Improving Care for Youth Act (TBD) Independent practice authority for psychologists in all Medicare-covered treatment settings Valuation of psychological and neuropsychological testing and evaluation services Coding and payment policy for prescribing psychologist services Hybrid payment models for primary care services CY 2027 Physician Fee Schedule proposed rule Payment and Coding for Intensive Behavioral Therapy (IBT) services Response to CMS RFI re: Medicaid/Medicare fraud/waste/abuse Meetings re: digital MH treatment device reimbursement in Medicare Proposed rule re: Medicaid state-directed payments","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":121695,"prefix":null,"prefix_display":null,"first_name":"DORIS","nickname":null,"middle_name":null,"last_name":"PARFAITE-CLAUDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140715,"prefix":"mr","prefix_display":"MR.","first_name":"JULIO","nickname":null,"middle_name":"CESAR","last_name":"ABREU","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":83012,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"STRICKLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"HR 1802 - SPARE Act S.1226 and H.R. 2587 - Youth Mental Health Research Act Kids Online Safety Act S.1748 Children's Online Privacy and Protection Act 2.0 S.836 National Institutes for Health Funding S.146 and H.R. 633 - TAKE IT DOWN Act Budget Reconciliation Bill - AI Moratorium AI Chatbot regulations H.R.2587 - Youth Mental Health Research Act KIDS Act SAGE AI Act HR 4876 / S. 2563 Improving Justice Through Science Act S.5090, Digital Age Assurance Act NIH Requests for Information NSF NPRM on federal grants Maternal Mental health","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":121695,"prefix":null,"prefix_display":null,"first_name":"DORIS","nickname":null,"middle_name":null,"last_name":"PARFAITE-CLAUDE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143455,"prefix":"mr","prefix_display":"MR.","first_name":"BENJAMIN","nickname":null,"middle_name":null,"last_name":"VONACHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145372,"prefix":"ms","prefix_display":"MS.","first_name":"KAREN CONWELL","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":75773,"prefix":null,"prefix_display":null,"first_name":"KENNETH","nickname":null,"middle_name":null,"last_name":"POLISHCHUK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":76,"name":"Natl Science Foundation (NSF)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 2036, S. 925 Credit for Caring Act H.R. 1151/S. 756 Freedom to Invest in Tomorrows Workforce Act Preservation of tax exemption for associations and charitable organizations in budget reconciliation H.R. 5145, Bipartisan Premium Tax Credit Extension Act Health care tax credits S. 1565/H.R. 138 Lowering Costs for Caregivers Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"S. 3466 Honor Our Promise to Veterans Act (the Honor Act) HR 1987 / S.926 SAVING VETERANS LIVES Act HR 4837/S. 3314 Written Informed Consent Act S. 3245 Medical Integrity in Necessary Diagnostics for (MIND) Our Veterans Act of 2025 S. 1868 Critical Access for Veterans Care Act of 2025 S. 2397 CARING (Coordinating and Aligning Records to Improve and Normalize Governance) for Our Veterans Health Act of 2025 Privacy and Confidentiality, Return to Work Implementation Fox Grant Suicide Prevention Program Reauthorization Veterans Community Care Program (VCCP) H.R. 740 / S. 275, Veterans ACCESS Act of 2025 H.R 1969, No Wrong Door for Veterans Act S. 1139, Hope for Heroes Act S. 4162, Get Justice-Involved Veterans BACK HOME Act VA psychology workforce shortages, Title 38 VA prescribing privileges for psychologists Psychedelic assisted therapy VA Research Veteran Suicide Prevention HR 5535 Veteran Service Recognition Act VA Hiring Freeze Impact on Research VA Clinical Practice Guidelines S. 702/H.R. 2426 Veterans Mental Health and Addiction Therapy Quality of Care Act Veteran Reproductive Health Services S. 787 VetPAC Act of 2025 H.R. 2283, Recognizing Community Organizations for Veteran Engagement and Recovery Act or the RECOVER Act Veterans Health Desert Reform Act (draft) H.R. 6993, Veterans TBI Breakthrough Exploration of Adaptive Care Opportunities Nationwide Act of 2026 or the BEACON Act of 2026 H.R. 8486, Data Driven Suicide Prevention Act (draft) H.R. 4509, NOPAIN for Veterans Act H.R. 6526, Clarity on Care Options Act H.R. 6848, Whole Health for Veterans Act S. 4744 / H.R. 9237, the Take Care of Americas Veterans Act H.R. 9533, Veterans Health Administration Personnel Transparency and Accountability Act H.R. 9376 TOURS Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140323,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"MCGUIRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145372,"prefix":"ms","prefix_display":"MS.","first_name":"KAREN CONWELL","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141050,"prefix":null,"prefix_display":null,"first_name":"STEFANIE","nickname":null,"middle_name":null,"last_name":"REEVES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143455,"prefix":"mr","prefix_display":"MR.","first_name":"BENJAMIN","nickname":null,"middle_name":null,"last_name":"VONACHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/de974cab-3649-4d2e-a10a-3181f5e93113/","filing_uuid":"de974cab-3649-4d2e-a10a-3181f5e93113","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/de974cab-3649-4d2e-a10a-3181f5e93113/print/","filing_document_content_type":"text/html","income":null,"expenses":"54762.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Colette Alston","dt_posted":"2026-10-19T11:43:51-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 12th Street NW","registrant_address_2":"Suite 700","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":400577734,"url":"https://lda.gov/api/v1/registrants/400577734/","house_registrant_id":null,"name":"ASSOCIATION FOR BEHAVIORAL HEALTH AND WELLNESS","description":"ABHW is the national voice for companies that manage behavioral health & wellness services","address_1":"700 12th Street NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"COLETTE ALSTON","contact_telephone":"+1 202-499-2280","dt_updated":"2026-07-20T08:21:58.745723-04:00"},"client":{"id":192996,"url":"https://lda.gov/api/v1/clients/192996/","client_id":12,"name":"ASSOCIATION FOR BEHAVIORAL HEALTH AND WELLNESS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-11-21"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-Suicide prevention and crisis services -Behavioral Health Workforce Shortages - Mental Health and Substance Use Disorder Parity - advocating for uniformity and clearer regulations for non-quantitative treatment limitations - Telehealth Expansion Act of 2025 - ABA for Autism","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71094,"prefix":null,"prefix_display":null,"first_name":"MAEGHAN","nickname":null,"middle_name":null,"last_name":"GILMORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141004,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148243,"prefix":"ms","prefix_display":"MS.","first_name":"DEBORAH","nickname":null,"middle_name":"MILLER","last_name":"WITCHEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":154409,"prefix":null,"prefix_display":null,"first_name":"LYDIA","nickname":null,"middle_name":null,"last_name":"HOMOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"},{"id":41,"name":"Treasury, Dept of"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"-Expand access to medication-assisted treatment -Drug Enforcement Agency (DEA) - rules for prescribing controlled medications via telemedicine -Contingency Management -Modernizing Opioid Treatment Access Act (MOTAA) 2.0 (S. 4941) -H.R. 5629 - bill to nullify SAMHSA rule -Teleprescribing for controlled substances -SUD treatment facility fraud","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71094,"prefix":null,"prefix_display":null,"first_name":"MAEGHAN","nickname":null,"middle_name":null,"last_name":"GILMORE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":141004,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148243,"prefix":"ms","prefix_display":"MS.","first_name":"DEBORAH","nickname":null,"middle_name":"MILLER","last_name":"WITCHEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154409,"prefix":null,"prefix_display":null,"first_name":"LYDIA","nickname":null,"middle_name":null,"last_name":"HOMOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"},{"id":41,"name":"Treasury, Dept of"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"-Telehealth, reforming barriers to access to services. Extending flexibilities and repealing the 6-month in person visit requirement. -The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act -Medicaid reform -Medicaid community engagement requirements -42 CFR Part 2 as it relates to Medicaid community engagement requirements -Coverage of Peer Support specialists' services","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71094,"prefix":null,"prefix_display":null,"first_name":"MAEGHAN","nickname":null,"middle_name":null,"last_name":"GILMORE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":141004,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"COHEN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148243,"prefix":"ms","prefix_display":"MS.","first_name":"DEBORAH","nickname":null,"middle_name":"MILLER","last_name":"WITCHEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154409,"prefix":null,"prefix_display":null,"first_name":"LYDIA","nickname":null,"middle_name":null,"last_name":"HOMOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"},{"id":41,"name":"Treasury, Dept of"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5076ee4d-ae05-4729-b0eb-220b1713d56b/","filing_uuid":"5076ee4d-ae05-4729-b0eb-220b1713d56b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5076ee4d-ae05-4729-b0eb-220b1713d56b/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-10-20T06:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5076ee4d-ae05-4729-b0eb-220b1713d56b/","filing_uuid":"5076ee4d-ae05-4729-b0eb-220b1713d56b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5076ee4d-ae05-4729-b0eb-220b1713d56b/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-10-20T06:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5076ee4d-ae05-4729-b0eb-220b1713d56b/","filing_uuid":"5076ee4d-ae05-4729-b0eb-220b1713d56b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5076ee4d-ae05-4729-b0eb-220b1713d56b/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-10-20T06:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5076ee4d-ae05-4729-b0eb-220b1713d56b/","filing_uuid":"5076ee4d-ae05-4729-b0eb-220b1713d56b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5076ee4d-ae05-4729-b0eb-220b1713d56b/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-10-20T06:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5076ee4d-ae05-4729-b0eb-220b1713d56b/","filing_uuid":"5076ee4d-ae05-4729-b0eb-220b1713d56b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5076ee4d-ae05-4729-b0eb-220b1713d56b/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-10-20T06:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5076ee4d-ae05-4729-b0eb-220b1713d56b/","filing_uuid":"5076ee4d-ae05-4729-b0eb-220b1713d56b","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5076ee4d-ae05-4729-b0eb-220b1713d56b/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kelly Corredor","dt_posted":"2026-10-20T06:22:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"11400 Rockville Pike","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20852","registrant":{"id":401104864,"url":"https://lda.gov/api/v1/registrants/401104864/","house_registrant_id":null,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","description":"Medical Professional Society","address_1":"11400 Rockville Pike","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20852","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CAROLYN C. LANHAM","contact_telephone":"+1 301-547-4104","dt_updated":"2026-07-17T06:37:18.428913-04:00"},"client":{"id":202836,"url":"https://lda.gov/api/v1/clients/202836/","client_id":12,"name":"AMERICAN SOCIETY OF ADDICTION MEDICINE","general_description":"Medical Professional Society","client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-05-01"},"lobbying_activities":[{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for introduction of Residential Recovery for Seniors Act (H.R.9538). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs. Advocated for S. 4941 / H.R. 9790 - the Modernizing Opioid Treatment Access Act 2.0, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Sent a public RFI response to HHS, calling for alignment of federal programs around evidence-based prevention, risk reduction, treatment engagement and retention, recovery support, and continuous quality improvement and encouraging a focus on federal policies that prioritize interventions supported by rigorous evidence; reduce administrative barriers that disrupt patient care; expand access through telehealth and team-based models; and modernize data systems to support continued learning Sent a public comment letter to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research. Joined coalition letter to the Centers for Medicare & Medicaid Services (CMS) regarding its issuance of a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments. The letter urges the agency not to finalize the proposed rule, which risks negatively impacting clinicians providing substance use disorder treatment and the ability for patients to access care. Submitted comment letter to the US Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) regarding the agency's Interim Final Rule (IFR) implementing Medicaid community engagement/work reporting requirements. While ASAM emphasized that meaningful community engagement, including employment, can be an important component of recovery, participating in those activities is fundamentally different from complying with ongoing administrative reporting and verification requirements that could undermine recovery by creating barriers to maintaining Medicaid coverage and access to treatment. Submitted public comment letter to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH), recognizing concerns about the risks associated with concentrated 7-OH products, including dependence, withdrawal, inconsistent product composition, and limited regulatory oversight. ASAM highlighted that the current scientific evidence is insufficient to support any specific concentration or quantity threshold as a validated indicator of an imminent public safety risk. Submitted public comment letter to the Centers for Medicare & Medicaid Services (CMS) in response to the agency's Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Highlighted the growing volume and complexity of alcohol and drug-related hospital encounters and pointed to the Society's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care as a roadmap for strengthening addiction treatment in hospital and emergency department settings. Sent public comment letter to the Centers for Medicare & Medicaid Services (CMS) recently proposed its CY 2027 Medicare Physician Fee Schedule (MPFS), urging CMS to support access to addiction treatment by delaying proposed practice expense changes, increasing payment for key prevention and treatment services, expanding telehealth flexibilities for intensive outpatient services, opposing payment cuts for certain evaluation and management services, updating policies related to extended-release buprenorphine, and developing future payment models that better recognize medically managed outpatient addiction care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":68378,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CORREDOR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":155,"name":"Drug Enforcement Administration (DEA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":19,"name":"Office of Natl Drug Control Policy (NDCP)"},{"id":1,"name":"SENATE"},{"id":141,"name":"Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5643b489-5544-4fa3-84a3-ecdbd16da388/","filing_uuid":"5643b489-5544-4fa3-84a3-ecdbd16da388","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5643b489-5544-4fa3-84a3-ecdbd16da388/print/","filing_document_content_type":"text/html","income":null,"expenses":"393240.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"Jeanne Slade","dt_posted":"2026-10-21T09:34:00-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"901 New York Ave NW","registrant_address_2":"Suite 515E","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":1967,"url":"https://lda.gov/api/v1/registrants/1967/","house_registrant_id":31721,"name":"AMERICAN COLLEGE OF EMERGENCY PHYSICIANS","description":null,"address_1":"901 New York Ave NW","address_2":"Suite 515E","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JEANNE SLADE","contact_telephone":"+1 202-728-0610","dt_updated":"2026-08-12T14:16:18.317337-04:00"},"client":{"id":102670,"url":"https://lda.gov/api/v1/clients/102670/","client_id":12,"name":"AMERICAN COLLEGE OF EMERGENCY PHYSICIANS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"1996-02-14"},"lobbying_activities":[{"general_issue_code":"TRA","general_issue_code_display":"Transportation","description":"H.R. 2992-Preventing Roadside and Work Zone Deaths Act, to require the Department of Transportation to collect, analyze, compile, and publish accurate, detailed data on disabled roadside vehicle crashes and work zone crashes to develop a strategic plan to stop these incidents.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Director, NEMPAC and ACEP Grassroots Advocacy","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ALC","general_issue_code_display":"Alcohol and Drug Abuse","description":"Opioids, pain management Federal funding for substance use disorder treatments H.R.2004-Tylers Law, to direct the Secretary of Health and Human Services to issue guidance on whether hospital emergency departments should implement routine fentanyl testing for patients experiencing an overdose H.R. 2483-Support for Patients and Communities Reauthorization Act, to reauthorize grants and programs to address opioid and substance use disorder H.R. 7994-Helping Educators Respond to Overdoses Act, to establish a grant program to provide schools with opioid overdose reversal drugs, to direct schools receiving Federal funds to report to certain Federal information systems any distribution of an opioid overdose reversal drug, and for other purposes H.R. 9790-Modernizing Opioid Treatment Access Act 2.0, to expand access to methadone through alternative care models using pharmacies S.921-Tylers Law, to direct the Secretary of Health and Human Services to issue guidance on whether hospital emergency departments should implement routine fentanyl testing for patients experiencing an overdose S. 2121-Support for Patients and Communities Reauthorization Act, to reauthorize grants and programs to address opioid and substance use disorder S. 3522-No Red Tape for Addiction Treatment Act, to require that State Medicaid programs provide at least one formulation of each type of medication for the treatment of opioid use disorder without prior authorization or limitations on dosage S. 4941-Modernizing Opioid Treatment Access Act 2.0, to expand access to methadone through alternative care models using pharmacies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding to implement Preventing Overdoses While in Emergency Rooms (POWER) program Federal funding to implement MISSION ZERO program Federal funding to for firearm safety and injury prevention research Federal funding to implement Emergency Medical Services for Children (EMSC) Federal funding for emergency medicine research activities Federal funding for implementation of Dr. Lorna Breen Health Care Provider Protection Act H.R. 5371, Continuing Appropriations and Extension Act, 2026, to provide appropriations for federal agencies and extend several public health, Medicare, and Medicaid authorities and programs H.R.7148-Consolidated Appropriations Act, 2026, to provide appropriations for federal agencies and extend several public health, Medicare, and Medicaid authorities and programs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DIS","general_issue_code_display":"Disaster Planning/Emergencies","description":"Access to emergency medical supplies (including Personal Protective Equipment, COVID-19 tests, ventilators, and medications) during COVID-19 public health emergency Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy and Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"H.R.2028-REDI Act, to amend the Higher Education Act of 1965 to provide for interest-free deferment on student loans for borrowers serving in a medical or dental internship or residency program. S.942-REDI Act, to amend the Higher Education Act of 1965 to provide for interest-free deferment on student loans for borrowers serving in a medical or dental internship or residency program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Advocacy","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FIR","general_issue_code_display":"Firearms/Guns/Ammunition","description":"Federal funding for firearms safety and injury prevention research Firearms safety and injury prevention policy H.R.5178-Sickle Cell Disease Comprehensive Care Act, to enable State Medicaid programs to provide comprehensive, coordinated care through a health home to individuals with sickle cell disease S. 1595-Sickle Cell Disease Comprehensive Care Act, to enable State Medicaid programs to provide comprehensive, coordinated care through a health home to individuals with sickle cell disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Reproductive health, physician-patient relationship, and EMTALA issues Emergency department boarding Drug shortages Health care consolidation H.R. 929-Dr. Lorna Breen Health Care Provider Protection Act, to reauthorize programs to improve mental health access for health care providers H.R. 1254-Rural Obstetrics Readiness Act, to improve obstetric emergency care H.R. 2414-To reauthorize the MISSION ZERO military-civilian partnership for trauma readiness H.R. 2936-Addressing Boarding and Crowding in the Emergency Department (ABC-ED) Act, to amend the Public Health Service Act to allow certain public health data modernization grants to be used to track hospital bed capacity, and for other purposes H.R. 3134-Emergency Care Improvement Act, to permanently allow for coverage under Medicare and Medicaid of services that are provided by freestanding emergency centers H.R. 3443-When Minutes Count for Emergency Medical Patients Act, to create a model, and to direct the Medicare Payment Advisory Commission to carry out a study and report with respect to Medicare payment for emergency medical services H.R. 3266-Mental Health Infrastructure Improvement Act of 2025, to make loans and loan guarantees for planning, constructing, or renovating pediatric or adult mental health treatment facilities and pediatric or adult substance use disorder treatment facilities H.R. 3980-Streamline Emergency Care Act, to authorize the Secretary of Health and Human Services to award grants for expanding, modernizing, or streamlining emergency department operations H.Res. 1519, Supporting the designation of September 17, 2026, as National Physician Suicide Awareness Day to raise awareness of, and promote a national discussion about, physician suicide and to reduce the stigma of mental health conditions, and for other purposes S. 266-Dr. Lorna Breen Health Care Provider Protection Act, to reauthorize programs to improve mental health access for health care providers S. 380- Rural Obstetrics Readiness Act, to improve obstetric emergency care S. 1673-Mental Health Infrastructure Improvement Act of 2025, to make loans and loan guarantees for planning, constructing, or renovating pediatric or adult mental health treatment facilities and pediatric or adult substance use disorder treatment facilities S. 1974-Addressing Boarding and Crowding in the Emergency Department (ABC-ED) Act, to amend the Public Health Service Act to allow certain public health data modernization grants to be used to track hospital bed capacity, and for other purposes","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"No Surprises Act implementation Eliminating prior authorization requirements in Medicare Advantage H.R. 2433-Reducing Unnecessary Medical Delays in Care Act of 2025, to ensure that prior authorization medical decisions under Medicare are determined by physicians. H.R. 3514-Improving Seniors Timely Access to Care Act of 2025, to improve and streamline prior authorization under Medicare Advantage Plans H.R. 4710-No Surprises Act Enforcement Act, to increase penalties for group health plans and health insurance issuers for practices that violate balance billing requirements. S. 1816-Improving Seniors Timely Access to Care Act of 2025, to improve and streamline prior authorization under Medicare Advantage Plans S. 2420- No Surprises Act Enforcement Act, to increase penalties for group health plans and health insurance issuers for practices that violate balance billing requirements.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Workplace violence prevention for health care workers H.R. 2531-Workplace Violence Prevention for Health Care and Social Service Workers Act, to require OSHA to issue workplace violence prevention standards to protect health care and social service workers H.R. 3413-Physician and Patient Safety Act, to provide due process protections for physicians H.R. 3791-EMS Counts Act, to ensure more accurate counts of trained EMS personnel by Bureau of Labor Statistics H.R. 10215-Workforce Mobility Act of 2025, to prohibit the use of noncompete agreements S. 1232-Workplace Violence Prevention for Health Care and Social Service Workers Act, to require OSHA to issue workplace violence prevention standards to protect health care and social service workers S. 1767-Physician and Patient Safety Act, to provide due process protections for physicians S. 2031-Workforce Mobility Act of 2025, to prohibit the use of noncompete agreements","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Federal funding for emergency medicine research activities","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Physician payment reform Counting observation stays as satisfying Medicare three-day inpatient stay prerequisite for skilled nursing facility (SNF) coverage H.R. 1-One Big Beautiful Bill Act, to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 539-Chiropractic Medicare Coverage Modernization Act of 2025, to amend title XVIII of the Social Security Act to provide Medicare coverage for all physicians services furnished by doctors of chiropractic within the scope of their license, and for other purposes. H.R. 771-Rural Health Care Access Act of 2025, to eliminate the 35-mile requirement to qualify as a critical access hospital H.R. 772-Rural ER Access Act, to require the Centers for Medicare and Medicaid Services to repeal the 35-mile requirement for off-campus facilities H.R. 879- Medicare Patient Access and Practice Stabilization Act of 2025, to address the 2025 Medicare Physician Fee Schedule cuts and increaser support for physicians and other practitioners in adjusting to Medicare payment changes H.R.1968-Full-Year Continuing Appropriations and Extensions Act, to provide appropriations for federal departments and agencies and to provide an increase for the calendar year 2024 physician fee schedule conversion factor H.R. 2433-Reducing Unnecessary Medical Delays in Care Act of 2025, to ensure that prior authorization medical decisions under Medicare are determined by physicians. H.R. 3164-Ensuring Community Access to Pharmacist Services Act (ECAPS) Act, to amend title XVIII of the Social Security Act to provide pharmacy payment of certain services H.R. 4206-CONNECT for Health Act, to expand access to telehealth services H.R. 6160-Strengthening Medicare for Patients and Providers Act, provide for an update to a single conversion factor under the Medicare physician fee schedule that is based on the Medicare economic index H.R. 6721-Medicare Advance Planning for Care Act, to encourage Medicare beneficiaries to voluntarily adopt advance directives guiding the medical care they receive H.R. 7520-Efficiency Adjustment Delay Act, to delay the implementation of an efficiency adjustment to work relative value units under the Medicare physician fee schedule H.R. 8163-Provider Reimbursement Stability Act, ensure stability for provider payments under the Medicare program H.R. 8500-Timely Access to Coverage Decisions Act of 2026, to amend title XVIII of the Social Security Act to ensure timely review of local coverage determination requests under the Medicare program H.R. 8622-Medicare Data-driven Performance Payment System Act of 2026, to transform the Merit-based Incentive Payment System into the Data-driven Performance Payment System under the Medicare physician fee schedule H.R. 9693-Patients First Act of 2026, to modify certain physician payments under the Medicare program S. 106-Chiropractic Medicare Coverage Modernization Act of 2025, to amend title XVIII of the Social Security Act to provide Medicare coverage for all physicians services furnished by doctors of chiropractic within the scope of their license, and for other purposes. S.1261-CONNECT for Health Act, to expand access to telehealth services S. 1640- Medicare Patient Access and Practice Stabilization Act of 2025, to address the 2025 Medicare Physician Fee Schedule cuts and increaser support for physicians and other practitioners in adjusting to Medicare payment changes S. 2426-Ensuring Community Access to Pharmacist Services Act (ECAPS) Act, to amend title XVIII of the Social Security Act to provide pharmacy payment of certain services S. 3473-Medicare Advance Planning for Care Act, to encourage Medicare beneficiaries to voluntarily adopt advance directives guiding the medical care they receive S. 4927-Rural Hospital Emergency Room Guarantee Act, to establish a guaranteed funding stream to keep existing emergency rooms at America's rural hospitals open.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LAW","general_issue_code_display":"Law Enforcement/Crime/Criminal Justice","description":"Fentanyl analogues scheduling extension H.R. 3178-Save Healthcare Workers Act, to establish federal criminal penalties for violence against health care workers H.R. 5864-Improving Police CARE Act, to provide standards for trauma kits purchased using Byrne JAG grant funds S. 1595-Improving Police CARE Act, to provide standards for trauma kits purchased using Byrne JAG grant funds S. 1600-Save Healthcare Workers Act, to establish federal criminal penalties for violence against health care workers","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy & Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AVI","general_issue_code_display":"Aviation/Airlines/Airports","description":"Updating first aid and emergency medical kits and flight crew training requirements","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67306,"prefix":null,"prefix_display":null,"first_name":"RYAN","nickname":null,"middle_name":null,"last_name":"MCBRIDE","suffix":null,"suffix_display":null},"covered_position":"Congressional Affairs Director","new":false},{"lobbyist":{"id":17845,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"SLADE","suffix":null,"suffix_display":null},"covered_position":"Senior Director, Grassroots Advocacy and Political Affairs","new":false},{"lobbyist":{"id":153871,"prefix":null,"prefix_display":null,"first_name":"HANNA","nickname":null,"middle_name":null,"last_name":"AHMARIPOUR","suffix":null,"suffix_display":null},"covered_position":"Congressional Lobbyist","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}